CY1117177T1 - Διεργασια για την παρασκευη [(3-υδροξυπυριδινο-2-καρβονυλ)αμινο]αλκανοϊκων οξεων, εστερων και αμιδιων - Google Patents
Διεργασια για την παρασκευη [(3-υδροξυπυριδινο-2-καρβονυλ)αμινο]αλκανοϊκων οξεων, εστερων και αμιδιωνInfo
- Publication number
- CY1117177T1 CY1117177T1 CY20161100037T CY161100037T CY1117177T1 CY 1117177 T1 CY1117177 T1 CY 1117177T1 CY 20161100037 T CY20161100037 T CY 20161100037T CY 161100037 T CY161100037 T CY 161100037T CY 1117177 T1 CY1117177 T1 CY 1117177T1
- Authority
- CY
- Cyprus
- Prior art keywords
- carbonyl
- amino
- acids
- preparation
- alcohanic
- Prior art date
Links
- -1 3-HYDROXYPYRIDIN-2-CARBONYL Chemical class 0.000 title abstract 3
- 239000002253 acid Substances 0.000 title abstract 3
- 150000007513 acids Chemical class 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 3
- 150000001408 amides Chemical class 0.000 title 1
- IZQMRNMMPSNPJM-UHFFFAOYSA-N 2-[(3-hydroxypyridine-2-carbonyl)amino]acetic acid Chemical compound OC(=O)CNC(=O)C1=NC=CC=C1O IZQMRNMMPSNPJM-UHFFFAOYSA-N 0.000 abstract 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Natural products CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 abstract 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 2
- 102000004079 Prolyl Hydroxylases Human genes 0.000 abstract 1
- 108010043005 Prolyl Hydroxylases Proteins 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J31/00—Catalysts comprising hydrides, coordination complexes or organic compounds
- B01J31/16—Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes
- B01J31/24—Phosphines, i.e. phosphorus bonded to only carbon atoms, or to both carbon and hydrogen atoms, including e.g. sp2-hybridised phosphorus compounds such as phosphabenzene, phosphole or anionic phospholide ligands
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/79—Acids; Esters
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/79—Acids; Esters
- C07D213/803—Processes of preparation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2531/00—Additional information regarding catalytic systems classified in B01J31/00
- B01J2531/80—Complexes comprising metals of Group VIII as the central metal
- B01J2531/82—Metals of the platinum group
- B01J2531/824—Palladium
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Materials Engineering (AREA)
- Inorganic Chemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- Cardiology (AREA)
- Ophthalmology & Optometry (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Enzymes And Modification Thereof (AREA)
- Curing Cements, Concrete, And Artificial Stone (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161493536P | 2011-06-06 | 2011-06-06 | |
| EP12796374.2A EP2718265B1 (en) | 2011-06-06 | 2012-06-05 | Process for preparing [(3-hydroxypyridine-2-carbonyl)amino]alkanoic acids, esters and amides |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1117177T1 true CY1117177T1 (el) | 2017-04-05 |
Family
ID=47262177
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20161100037T CY1117177T1 (el) | 2011-06-06 | 2016-01-14 | Διεργασια για την παρασκευη [(3-υδροξυπυριδινο-2-καρβονυλ)αμινο]αλκανοϊκων οξεων, εστερων και αμιδιων |
| CY20171101202T CY1119605T1 (el) | 2011-06-06 | 2017-11-15 | Παραγωγα 5-αρυλο ή 5-ετεροαρυλο υποκατεστημενου 3-υδροξυπυριδιν-2-υλ-καρβονυλαμινο-αλκανοϊκου οξεος και αλατα αυτων καθως και παρασκευη τους απο τα αντιστοιχα παραγωγα 3-υδροξυ-πικολινικου οξεος |
| CY20201100087T CY1122639T1 (el) | 2011-06-06 | 2020-02-03 | Παραγωγα 5-((αλογονοφαινυλ)-3-αλογονο-πυριδιν-2-υλ)-νιτριλιου ως ενδιαμεσα στην παρασκευη παραγωγων [(5-αλογονοφαινυλ)-3-υδροξυπυριδινο-2-καρβονυλ)- αμινο]αλκανοϊκου οξεος |
| CY20211101079T CY1124874T1 (el) | 2011-06-06 | 2021-12-08 | Διεργασια για την παρασκευη [(5-(3-χλωροφαινυλ)-3-υδροξυπυριδινο-2-καρβονυλ)-αμινο]οξικου οξεος απο 5-((3-χλωροφαινυλ)-3-χλωρο-πυριδιν-2-υλ)-νιτριλιο, και διεργασια για την παρασκευη παραγωγων 5-((αλογονοφαινυλ)-3-αλογονο-πυριδιν-2-υλ)-νιτριλιου |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20171101202T CY1119605T1 (el) | 2011-06-06 | 2017-11-15 | Παραγωγα 5-αρυλο ή 5-ετεροαρυλο υποκατεστημενου 3-υδροξυπυριδιν-2-υλ-καρβονυλαμινο-αλκανοϊκου οξεος και αλατα αυτων καθως και παρασκευη τους απο τα αντιστοιχα παραγωγα 3-υδροξυ-πικολινικου οξεος |
| CY20201100087T CY1122639T1 (el) | 2011-06-06 | 2020-02-03 | Παραγωγα 5-((αλογονοφαινυλ)-3-αλογονο-πυριδιν-2-υλ)-νιτριλιου ως ενδιαμεσα στην παρασκευη παραγωγων [(5-αλογονοφαινυλ)-3-υδροξυπυριδινο-2-καρβονυλ)- αμινο]αλκανοϊκου οξεος |
| CY20211101079T CY1124874T1 (el) | 2011-06-06 | 2021-12-08 | Διεργασια για την παρασκευη [(5-(3-χλωροφαινυλ)-3-υδροξυπυριδινο-2-καρβονυλ)-αμινο]οξικου οξεος απο 5-((3-χλωροφαινυλ)-3-χλωρο-πυριδιν-2-υλ)-νιτριλιο, και διεργασια για την παρασκευη παραγωγων 5-((αλογονοφαινυλ)-3-αλογονο-πυριδιν-2-υλ)-νιτριλιου |
Country Status (23)
| Country | Link |
|---|---|
| US (6) | US9145366B2 (enExample) |
| EP (5) | EP3000808B1 (enExample) |
| JP (6) | JP6290781B2 (enExample) |
| KR (5) | KR102293016B1 (enExample) |
| CN (1) | CN106518759B (enExample) |
| AU (4) | AU2012268426B2 (enExample) |
| CA (2) | CA3135440A1 (enExample) |
| CY (4) | CY1117177T1 (enExample) |
| DK (4) | DK3683209T3 (enExample) |
| ES (4) | ES2647602T3 (enExample) |
| HR (4) | HRP20211916T1 (enExample) |
| HU (4) | HUE057571T2 (enExample) |
| IL (1) | IL229775A (enExample) |
| LT (3) | LT3290404T (enExample) |
| MX (2) | MX347709B (enExample) |
| NO (1) | NO2686520T3 (enExample) |
| PL (4) | PL3290404T3 (enExample) |
| PT (4) | PT3000808T (enExample) |
| RS (3) | RS56580B1 (enExample) |
| RU (2) | RU2764667C2 (enExample) |
| SI (4) | SI3683209T1 (enExample) |
| SM (3) | SMT202000061T1 (enExample) |
| WO (1) | WO2012170377A1 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3357911T3 (pl) | 2006-06-26 | 2022-09-05 | Akebia Therapeutics Inc. | Inhibitory prolilohydroksylazy i sposoby ich użycia |
| NO2686520T3 (enExample) | 2011-06-06 | 2018-03-17 | ||
| PE20160194A1 (es) * | 2013-06-13 | 2016-04-20 | Akebia Therapeutics Inc | Composiciones y metodos para tratar anemia |
| TW201946625A (zh) * | 2013-11-15 | 2019-12-16 | 美商阿克比治療有限公司 | {[5-(3-氯苯基)-3-羥基吡啶-2-羰基]胺基}乙酸之固體型式，其組合物及用途 |
| WO2016034108A1 (zh) | 2014-09-02 | 2016-03-10 | 广东东阳光药业有限公司 | 喹啉酮类化合物及其应用 |
| AU2016209126A1 (en) | 2015-01-23 | 2017-08-10 | Akebia Therapeutics, Inc. | Solid forms of 2-(5-(3-fluorophenyl)-3-hydroxypicolinamido)acetic acid, compositions, and uses thereof |
| US20180065933A1 (en) * | 2015-03-20 | 2018-03-08 | Akebia Therapeutics, Inc. | Deuterium-enriched hypoxia-inducible factor prolyl hydroxylase enzyme inhibitors |
| CN106146395B (zh) * | 2015-03-27 | 2019-01-01 | 沈阳三生制药有限责任公司 | 3-羟基吡啶化合物、其制备方法及其制药用途 |
| SG11201707994UA (en) | 2015-04-01 | 2017-10-30 | Akebia Therapeutics Inc | Compositions and methods for treating anemia |
| CA3046377C (en) * | 2016-12-13 | 2021-03-30 | Crystal Pharmaceutical (Suzhou) Co., Ltd. | Novel crystalline forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} acetic acid and processes for preparation thereof |
| IL269623B2 (en) * | 2017-03-29 | 2025-05-01 | Emerald Health Pharmaceuticals Inc | Cannabidiol derivatives as inhibitors of the hif prolyl hydroxylases activity |
| WO2019028150A1 (en) | 2017-08-01 | 2019-02-07 | Akebia Therapeutics, Inc. | COMPOSITIONS FOR USE IN METHODS OF TREATING HEMOGLOBINOPATHIES |
| AU2019265629B2 (en) | 2018-05-09 | 2024-09-12 | Akebia Therapeutics, Inc. | Process for preparing 2-((5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl)amino)acetic acid |
| WO2020075199A1 (en) | 2018-10-12 | 2020-04-16 | Mylan Laboratories Limited | Polymorphic forms of vadadustat |
| EP3887356B1 (en) | 2018-11-28 | 2023-08-02 | Sandoz AG | Multi-component crystals of an orally available hif prolyl hydroxylase inhibitor |
| JP7470106B2 (ja) * | 2019-04-26 | 2024-04-17 | 株式会社カネカ | Ｖａｄａｄｕｓｔａｔ中間体の製造方法 |
| US11524939B2 (en) | 2019-11-13 | 2022-12-13 | Akebia Therapeutics, Inc. | Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} acetic acid |
| CN111087343B (zh) * | 2019-11-29 | 2022-02-18 | 万华化学集团股份有限公司 | 一种羟基吡啶配体及其制备方法和催化应用 |
| US20230159462A1 (en) * | 2019-12-10 | 2023-05-25 | Akebia Therapeutics, Inc. | Method for producing nitrogen-containing heteroarylcarboxamide acetic acid derivative |
| CN115023288A (zh) | 2020-01-24 | 2022-09-06 | 先技精工(日本)有限公司 | 光催化组件和包括该光催化组件的口罩 |
| US20230286918A1 (en) * | 2020-07-02 | 2023-09-14 | Akebia Therapeutics, Inc. | Manufacturing process for 3,5-dichloropicolinonitrile for synthesis of vadadustat |
| GB202011431D0 (en) * | 2020-07-23 | 2020-09-09 | Johnson Matthey Plc | Polymorphs of vadadustat and methods for preparing the polymorphs |
| CN118715015A (zh) | 2021-12-17 | 2024-09-27 | 阿克比治疗有限公司 | 选择性phd1抑制剂化合物、组合物和使用方法 |
| WO2024165507A1 (en) | 2023-02-06 | 2024-08-15 | Institut National de la Santé et de la Recherche Médicale | Use of hif-1α stabilizing agents for the treatment of type i interferonopathies |
Family Cites Families (111)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3655679A (en) | 1969-06-25 | 1972-04-11 | Merck & Co Inc | Certain aryl pyridine carboxylic acid derivatives |
| US3703582A (en) * | 1970-04-20 | 1972-11-21 | Merck & Co Inc | Aryl pyridine carboxylic acids in the treatment of inflammation |
| US3894920A (en) | 1971-12-21 | 1975-07-15 | Sagami Chem Res | Process for preparing alkyl-substituted 3,6-dihydro-o-dioxin derivatives |
| US4016287A (en) | 1972-07-17 | 1977-04-05 | Boehringer Ingelheim Gmbh | Dermatological compositions containing an acylamino-carboxylic acid or an alkyl ester thereof |
| TW219933B (enExample) | 1990-02-26 | 1994-02-01 | Lilly Co Eli | |
| US5405613A (en) | 1991-12-11 | 1995-04-11 | Creative Nutrition Canada Corp. | Vitamin/mineral composition |
| TW352384B (en) | 1992-03-24 | 1999-02-11 | Hoechst Ag | Sulfonamido- or sulfonamidocarbonylpyridine-2-carboxamides, process for their preparation and their use as pharmaceuticals |
| DE4219158A1 (de) | 1992-06-11 | 1993-12-16 | Thomae Gmbh Dr K | Biphenylderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
| ES2101421T3 (es) | 1993-11-02 | 1997-07-01 | Hoechst Ag | Amidas de acidos carboxilicos heterociclicos sustituidos, su preparacion y su utilizacion como medicamentos. |
| EP0650960B1 (de) * | 1993-11-02 | 1997-03-05 | Hoechst Aktiengesellschaft | Substituierte heterocyclische Carbonsäureamidester, ihre Herstellung und ihre Verwendung als Arzneimittel |
| NZ270267A (en) | 1993-12-30 | 1997-03-24 | Hoechst Ag | 3-hydroxypyridin-2yl (and -quinolin-2-yl) carboxamide derivatives and pharmaceutical compositions |
| DE4410480A1 (de) | 1994-03-25 | 1995-09-28 | Hoechst Ag | Sulfonamidocarbonylpyridin-2-carbonsäureesteramide sowie ihre Pyridin-N-oxide, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| DE4410423A1 (de) | 1994-03-25 | 1995-09-28 | Hoechst Ag | Sulfonamidocarbonylpyridin-2-carbonsäureamide sowie ihre Pyridin-N-oxide, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| US5789426A (en) | 1995-01-20 | 1998-08-04 | Cornell Research Foundation, Inc. | Method for the treatment of fibroproliferative disorders by application of inhibitors of protein hydroxylation |
| IL135495A (en) | 1995-09-28 | 2002-12-01 | Hoechst Ag | Intermediate compounds for the preparation of quinoline-converted amines - 2 - carboxylic acid |
| JPH09221476A (ja) | 1995-12-15 | 1997-08-26 | Otsuka Pharmaceut Co Ltd | 医薬組成物 |
| KR20000065090A (ko) | 1996-04-30 | 2000-11-06 | 훽스트 악티엔게젤샤프트 | 3-알콕시피리딘-2-카복실산아미드에스테르,이의제조방법및약제로서의이의용도 |
| DE19620041A1 (de) | 1996-05-17 | 1998-01-29 | Merck Patent Gmbh | Adhäsionsrezeptor-Antagonisten |
| DE19650215A1 (de) | 1996-12-04 | 1998-06-10 | Hoechst Ag | 3-Hydroxypyridin-2-carbonsäureamidester, ihre Herstellung und ihre Verwendung als Arzneimittel |
| EP1024134A4 (en) | 1997-10-09 | 2003-05-14 | Ono Pharmaceutical Co | DERIVATIVES OF AMINOBUTANIC ACID |
| DE19746287A1 (de) | 1997-10-20 | 1999-04-22 | Hoechst Marion Roussel De Gmbh | Substituierte Isochinolin-2-Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel |
| AU757868B2 (en) | 1998-03-23 | 2003-03-06 | Aventis Pharmaceuticals Inc. | Piperididinyl and N-amidinopiperidinyl derivatives |
| US6159379A (en) | 1999-05-04 | 2000-12-12 | Baker Hughes Incorporated | Organic ammonium salts for the removal of water soluble organics in produced water |
| JP2001048786A (ja) | 1999-08-05 | 2001-02-20 | Yamanouchi Pharmaceut Co Ltd | 三環式ヘテロアリール誘導体 |
| US6589758B1 (en) | 2000-05-19 | 2003-07-08 | Amgen Inc. | Crystal of a kinase-ligand complex and methods of use |
| US6849718B2 (en) | 2001-03-20 | 2005-02-01 | Dana Farber Cancer Institute, Inc. | Muteins of hypoxia inducible factor alpha and methods of use thereof |
| US6855510B2 (en) | 2001-03-20 | 2005-02-15 | Dana Farber Cancer Institute, Inc. | Pharmaceuticals and methods for treating hypoxia and screening methods therefor |
| JP4590157B2 (ja) | 2001-03-21 | 2010-12-01 | アイシス イノヴェイション リミテッド | アッセイ、方法および手段 |
| SE0101327D0 (sv) | 2001-04-12 | 2001-04-12 | Astrazeneca Ab | New crystalline forms |
| US6566088B1 (en) | 2001-10-04 | 2003-05-20 | Board Of Regents, The University Of Texas System | Prolyl-4-hydroxylases |
| GB0124941D0 (en) | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
| EP1487472B1 (en) | 2001-12-06 | 2019-06-26 | Fibrogen, Inc. | Treatment of ischemic or hypoxic conditions using heterocyclic carboxamides |
| CN1668296A (zh) | 2002-05-17 | 2005-09-14 | 细胞基因公司 | 使用选择性细胞因子抑制性药物用于治疗和控制癌症和其它疾病的方法及组合物 |
| US7163951B2 (en) * | 2002-08-29 | 2007-01-16 | Merck & Co., Inc. | N-biarylmethyl aminocycloalkanecarboxamide derivatives |
| JP4465276B2 (ja) | 2002-10-16 | 2010-05-19 | イシス イノベイション リミテッド | アスパラギニルヒドロキシラーゼ及びその修飾物質 |
| EP1567528A1 (en) | 2002-11-21 | 2005-08-31 | Eli Lilly And Company | Mixed lineage kinase modulators |
| US8124582B2 (en) | 2002-12-06 | 2012-02-28 | Fibrogen, Inc. | Treatment of diabetes |
| US7618940B2 (en) | 2002-12-06 | 2009-11-17 | Fibrogen, Inc. | Fat regulation |
| US7183287B2 (en) | 2003-04-03 | 2007-02-27 | Pharmacia Corporation | Substituted pyrimidinones |
| US8614204B2 (en) | 2003-06-06 | 2013-12-24 | Fibrogen, Inc. | Enhanced erythropoiesis and iron metabolism |
| PL1644336T3 (pl) | 2003-06-06 | 2011-07-29 | Fibrogen Inc | Związki heteroarylowe zawierające azot i ich zastosowanie w zwiększaniu poziomu endogennej erytropoetyny |
| WO2005007192A2 (en) | 2003-06-06 | 2005-01-27 | Fibrogen, Inc. | Cytoprotection through the use of hif hydroxylase inhibitors |
| GB0314129D0 (en) | 2003-06-18 | 2003-07-23 | Astrazeneca Ab | Therapeutic agents |
| WO2005108370A1 (ja) | 2004-04-16 | 2005-11-17 | Ajinomoto Co., Inc. | ベンゼン化合物 |
| NZ551632A (en) | 2004-05-28 | 2009-09-25 | Fibrogen Inc | HIF prolyl hydroxylase activity assay |
| TW200609218A (en) | 2004-05-31 | 2006-03-16 | Tanabe Seiyaku Co | Bicyclic compounds |
| EA200700243A1 (ru) | 2004-07-14 | 2007-08-31 | ПиТиСи ТЕРАПЬЮТИКС, ИНК. | Способы лечения гепатита с |
| TW200616969A (en) | 2004-09-17 | 2006-06-01 | Tanabe Seiyaku Co | Imidazole compound |
| WO2006084210A2 (en) | 2005-02-04 | 2006-08-10 | Regents Of The University Of California, San Diego | Hif modulating compounds and methods of use thereof |
| DE102005019712A1 (de) | 2005-04-28 | 2006-11-09 | Bayer Healthcare Ag | Dipyridyl-dihydropyrazolone und ihre Verwendung |
| EP1893186A2 (en) | 2005-06-06 | 2008-03-05 | Fibrogen, Inc. | Improved treatment for anemia using a hif-alpha stabilising agent |
| BRPI0611670A2 (pt) | 2005-06-15 | 2016-11-16 | Fibrogen Inc | método para o tratamento ou prevenção de câncer em um indivíduo |
| WO2007033216A2 (en) | 2005-09-12 | 2007-03-22 | Beth Israel Deaconess Medical Center | Methods and compositions for the treatment and diagnosis of diseases characterized by vascular leak, hypotension, or a procoagulant state |
| WO2007038571A2 (en) | 2005-09-26 | 2007-04-05 | Smithkline Beecham Corporation | Prolyl hydroxylase antagonists |
| US20090176726A1 (en) | 2005-10-11 | 2009-07-09 | Fisher David E | Methods for treating mitf-related disorders |
| JP5202327B2 (ja) | 2005-12-09 | 2013-06-05 | アムジエン・インコーポレーテツド | プロリルヒドロキシラーゼ阻害活性を示すキノロンベースの化合物、およびこの組成物、およびこの使用 |
| GB2453819A (en) | 2006-01-09 | 2009-04-22 | Btg Int Ltd | Modulators of hypoxia inducible factor-1 and related uses |
| WO2007082899A1 (en) | 2006-01-17 | 2007-07-26 | Vib Vzw | Inhibitors of prolyl-hydroxylase 1 for the treatment of skeletal muscle degeneration |
| EP1979353A2 (en) | 2006-01-19 | 2008-10-15 | OSI Pharmaceuticals, Inc. | Fused heterobicyclic kinase inhibitors |
| JP4801451B2 (ja) | 2006-01-19 | 2011-10-26 | 株式会社日立ハイテクノロジーズ | 走査電子顕微鏡等に用いる電子銃の制御装置及び制御方法 |
| ITMI20060179A1 (it) | 2006-02-02 | 2007-08-03 | Abiogen Pharma Spa | Procedimento per la risoluzione di miscele racemiche e complesso diastereoisomerico di un agente risolvente e di unantiomero di interesse |
| US7625927B2 (en) | 2006-02-27 | 2009-12-01 | Alcon Research, Ltd. | Method of treating glaucoma |
| AR059733A1 (es) | 2006-03-07 | 2008-04-23 | Smithkline Beecham Corp | Compuesto derivado de glicina n- sustituida con heteroaromaticos bicicicos, composicion farmaceutica que lo comprende, uso para preparar un medicamento para tratar la anemia y proceso para su preparacion |
| US7588924B2 (en) | 2006-03-07 | 2009-09-15 | Procter & Gamble Company | Crystal of hypoxia inducible factor 1 alpha prolyl hydroxylase |
| WO2007136990A2 (en) | 2006-05-16 | 2007-11-29 | Smithkline Beecham Corporation | Prolyl hydroxylase inhibitors |
| AR061570A1 (es) | 2006-06-23 | 2008-09-03 | Smithkline Beecham Corp | Compuesto de glicina sustituido en el n heteroaromatico composicion farmaceutica que lo comprende, su uso para preparar un medicamento, procedimientos para preparar dicha composicion farmaceutica y para preparar el compuesto |
| PL3357911T3 (pl) | 2006-06-26 | 2022-09-05 | Akebia Therapeutics Inc. | Inhibitory prolilohydroksylazy i sposoby ich użycia |
| CL2008000066A1 (es) | 2007-01-12 | 2008-08-01 | Smithkline Beecham Corp | Compuestos derivados de (5-hidroxi-3-oxo-2,3-dihidropiridazina-4-carbonil)glicina, inhibidores de hif prolil hidroxilasas; procedimiento de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de la anem |
| CL2008000065A1 (es) | 2007-01-12 | 2008-09-22 | Smithkline Beecham Corp | Compuestos derivados de glicina n-sustituida, inhibidores de hif prolil hidroxilasas; su proceso de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de la anemia. |
| EP2136810A4 (en) | 2007-04-18 | 2012-01-04 | Merck Sharp & Dohme | NOVEL 1,8-NAPHTHYRIDINE COMPOUNDS |
| US7569726B2 (en) | 2007-04-18 | 2009-08-04 | Amgen Inc. | Indanone derivatives that inhibit prolyl hydroxylase |
| AU2008248234B2 (en) | 2007-05-04 | 2011-02-03 | Amgen Inc. | Thienopyridine and thiazolopyridine derivatives that inhibit prolyl hydroxylase activity |
| WO2008144266A1 (en) | 2007-05-16 | 2008-11-27 | Merck & Co., Inc. | Spiroindalones |
| AU2008253311A1 (en) | 2007-05-18 | 2008-11-27 | Bayer Schering Pharma Aktiengesellshaft | Inhibitors of hypoxia inducible factor (HIF) useful for treating hyper-proliferative disorders and diseases associated with angiogenesis |
| US8268794B2 (en) | 2007-08-06 | 2012-09-18 | Senju Pharmaceutical Co., Ltd. | Pharmaceutical containing HIF-1 alpha and HIF-2 alpha expression inhibitor |
| TW200908984A (en) | 2007-08-07 | 2009-03-01 | Piramal Life Sciences Ltd | Pyridyl derivatives, their preparation and use |
| CN101815718A (zh) | 2007-08-10 | 2010-08-25 | 克里斯捷诺米有限公司 | 吡啶衍生物及其用法 |
| WO2009035534A2 (en) | 2007-09-07 | 2009-03-19 | The Cleveland Clinic Foundation | Treatment of ischemic eye disease by the systematic pharmaceutical activation of hypoxia inducible factor (hif) |
| WO2009039323A1 (en) | 2007-09-19 | 2009-03-26 | Smithkline Beecham Corporation | Prolyl hydroxylase inhibitors |
| WO2009039321A1 (en) | 2007-09-19 | 2009-03-26 | Smithkline Beecham Corporation | Prolyl hydroxylase inhibitors |
| WO2009043093A1 (en) | 2007-10-04 | 2009-04-09 | Newsouth Innovations Pty Limited | Hif inhibition |
| WO2009049112A1 (en) | 2007-10-10 | 2009-04-16 | Smithkline Beecham Corporation | Prolyl hydroxylase inhibitors |
| WO2009067790A1 (en) | 2007-11-26 | 2009-06-04 | Uti Limited Partnership | STIMULATION OF HYPOXIA INDUCIBLE FACTOR -1 ALPHA (HIF-1α) FOR THE TREATMENT OF CLOSTRIDIUM DIFFICILE ASSOCIATED DISEASE (CDAD), FOR INTESTINAL MOTILITY AND FOR DETECTING INFECTION |
| JP2011508725A (ja) | 2007-11-30 | 2011-03-17 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | プロリルヒドロキシラーゼ阻害剤 |
| AU2008329746A1 (en) | 2007-11-30 | 2009-06-04 | Glaxosmithkline Llc | Prolyl hydroxylase inhibitors |
| US8269008B2 (en) | 2007-12-03 | 2012-09-18 | Fibrogen, Inc. | Oxazolopyridine and isoxazolopyridine derivatives for use in the treatment of HIF-mediated conditions |
| EP2240178A4 (en) | 2007-12-19 | 2011-10-26 | Glaxosmithkline Llc | PROLYLHYDROXYLASEHEMMER |
| US20110003013A1 (en) | 2008-01-04 | 2011-01-06 | Garvan Institute Of Medical Research | Method of increasing metabolism |
| EP2252619B1 (en) | 2008-01-11 | 2013-10-09 | Fibrogen, Inc. | Isothiazole-pyridine derivatives as modulators of hif (hypoxia inducible factor) activity |
| SI2268618T1 (sl) * | 2008-03-03 | 2015-09-30 | Novartis Ag | Spojine in sestavki kot modulatorji aktivnosti TLR |
| US20090228298A1 (en) * | 2008-03-04 | 2009-09-10 | The General Electric Company | System and method of morphology feature analysis of physiological data |
| CN102036558A (zh) * | 2008-03-20 | 2011-04-27 | 森林实验室控股有限公司 | 作为硬脂酰-CoA去饱和酶抑制剂的新颖哌啶衍生物 |
| AR071997A1 (es) | 2008-06-04 | 2010-07-28 | Bristol Myers Squibb Co | Forma cristalina de 6-((4s)-2-metil-4-(2-naftil)-1,2,3,4-tetrahidroisoquinolin-7-il)piridazin-3-amina |
| JP2011528686A (ja) * | 2008-07-23 | 2011-11-24 | エフ．ホフマン−ラ ロシュ アーゲー | ヘテロ環式抗ウイルス性化合物 |
| WO2010029577A2 (en) | 2008-09-15 | 2010-03-18 | Ganga Raju Gokaraju | Anti-cancer drugs and uses relating thereto for metastatic malignant melanoma and other cancers |
| EP2370422B1 (en) | 2008-11-14 | 2019-06-05 | Fibrogen, Inc. | Thiochromene derivatives as hif hydroxylase inhibitors |
| CA2755132C (en) * | 2009-03-31 | 2018-02-13 | Kissei Pharmaceutical Co., Ltd. | Indolizine derivative and use thereof for medical purposes |
| CN102638983B (zh) | 2009-11-06 | 2014-11-26 | 阿尔皮奥治疗学股份有限公司 | 用于治疗结肠炎的组合物和方法 |
| CA2837560C (en) | 2011-06-06 | 2017-02-14 | Akebia Therapeutics Inc. | Compounds and compositions for stabilizing hypoxia inducible factor-2 alpha as a method for treating cancer |
| NO2686520T3 (enExample) | 2011-06-06 | 2018-03-17 | ||
| WO2012174256A2 (en) | 2011-06-17 | 2012-12-20 | The Regents Of The University Of Michigan | Dna methylation profiles in cancer |
| KR102029951B1 (ko) | 2011-07-22 | 2019-11-08 | 베이징 베타 파머수티컬 컴퍼니 리미티드 | 프로릴 히드록실라제 억제제로서 화합물의 다형체형, 및 이의 용도 |
| US11491154B2 (en) | 2013-04-08 | 2022-11-08 | Dennis M. Brown | Therapeutic benefit of suboptimally administered chemical compounds |
| PE20160194A1 (es) | 2013-06-13 | 2016-04-20 | Akebia Therapeutics Inc | Composiciones y metodos para tratar anemia |
| JP2016529257A (ja) | 2013-08-16 | 2016-09-23 | オハイオ ステート イノベーション ファウンデーション | Ｄｎａメチル化を調節する組成物及び方法 |
| TW201946625A (zh) | 2013-11-15 | 2019-12-16 | 美商阿克比治療有限公司 | {[5-(3-氯苯基)-3-羥基吡啶-2-羰基]胺基}乙酸之固體型式，其組合物及用途 |
| EP3096617A4 (en) | 2014-01-23 | 2017-09-13 | Akebia Therapeutics Inc. | Compositions and methods for treating ocular diseases |
| AU2016209126A1 (en) | 2015-01-23 | 2017-08-10 | Akebia Therapeutics, Inc. | Solid forms of 2-(5-(3-fluorophenyl)-3-hydroxypicolinamido)acetic acid, compositions, and uses thereof |
| US20180065933A1 (en) | 2015-03-20 | 2018-03-08 | Akebia Therapeutics, Inc. | Deuterium-enriched hypoxia-inducible factor prolyl hydroxylase enzyme inhibitors |
| SG11201707994UA (en) | 2015-04-01 | 2017-10-30 | Akebia Therapeutics Inc | Compositions and methods for treating anemia |
| AU2019265629B2 (en) | 2018-05-09 | 2024-09-12 | Akebia Therapeutics, Inc. | Process for preparing 2-((5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl)amino)acetic acid |
-
2012
- 2012-03-05 NO NO12759983A patent/NO2686520T3/no unknown
- 2012-06-05 DK DK19214405.3T patent/DK3683209T3/da active
- 2012-06-05 KR KR1020207029586A patent/KR102293016B1/ko active Active
- 2012-06-05 HU HUE19214405A patent/HUE057571T2/hu unknown
- 2012-06-05 HU HUE17191362A patent/HUE048044T2/hu unknown
- 2012-06-05 EP EP15189822.8A patent/EP3000808B1/en active Active
- 2012-06-05 ES ES15189822.8T patent/ES2647602T3/es active Active
- 2012-06-05 KR KR1020147000297A patent/KR102000485B1/ko active Active
- 2012-06-05 AU AU2012268426A patent/AU2012268426B2/en active Active
- 2012-06-05 MX MX2015016579A patent/MX347709B/es unknown
- 2012-06-05 HR HRP20211916TT patent/HRP20211916T1/hr unknown
- 2012-06-05 SI SI201231969T patent/SI3683209T1/sl unknown
- 2012-06-05 EP EP17191362.7A patent/EP3290404B1/en active Active
- 2012-06-05 PT PT151898228T patent/PT3000808T/pt unknown
- 2012-06-05 PL PL17191362T patent/PL3290404T3/pl unknown
- 2012-06-05 RU RU2016139352A patent/RU2764667C2/ru active
- 2012-06-05 RS RS20171181A patent/RS56580B1/sr unknown
- 2012-06-05 RS RS20160013A patent/RS54517B1/sr unknown
- 2012-06-05 EP EP12796374.2A patent/EP2718265B1/en active Active
- 2012-06-05 MX MX2013014228A patent/MX337216B/es active IP Right Grant
- 2012-06-05 ES ES19214405T patent/ES2900572T3/es active Active
- 2012-06-05 SI SI201230432T patent/SI2718265T1/sl unknown
- 2012-06-05 KR KR1020197037296A patent/KR102171315B1/ko active Active
- 2012-06-05 CA CA3135440A patent/CA3135440A1/en active Pending
- 2012-06-05 LT LTEP17191362.7T patent/LT3290404T/lt unknown
- 2012-06-05 HR HRP20151416T patent/HRP20151416T1/hr unknown
- 2012-06-05 EP EP19214405.3A patent/EP3683209B1/en active Active
- 2012-06-05 KR KR1020197007633A patent/KR102032864B1/ko active Active
- 2012-06-05 SM SM20200061T patent/SMT202000061T1/it unknown
- 2012-06-05 ES ES12796374.2T patent/ES2559850T3/es active Active
- 2012-06-05 RS RS20200130A patent/RS59902B1/sr unknown
- 2012-06-05 ES ES17191362T patent/ES2771232T3/es active Active
- 2012-06-05 PT PT127963742T patent/PT2718265E/pt unknown
- 2012-06-05 LT LTEP15189822.8T patent/LT3000808T/lt unknown
- 2012-06-05 PL PL12796374T patent/PL2718265T3/pl unknown
- 2012-06-05 SM SM20170534T patent/SMT201700534T1/it unknown
- 2012-06-05 DK DK17191362.7T patent/DK3290404T3/da active
- 2012-06-05 PT PT171913627T patent/PT3290404T/pt unknown
- 2012-06-05 CA CA2838194A patent/CA2838194C/en active Active
- 2012-06-05 SI SI201231729T patent/SI3290404T1/sl unknown
- 2012-06-05 HU HUE12796374A patent/HUE026096T2/en unknown
- 2012-06-05 HU HUE15189822A patent/HUE034975T2/en unknown
- 2012-06-05 EP EP21206374.7A patent/EP4026829A1/en active Pending
- 2012-06-05 LT LTEP19214405.3T patent/LT3683209T/lt unknown
- 2012-06-05 PL PL15189822T patent/PL3000808T3/pl unknown
- 2012-06-05 DK DK15189822.8T patent/DK3000808T3/da active
- 2012-06-05 JP JP2014514536A patent/JP6290781B2/ja active Active
- 2012-06-05 US US13/488,554 patent/US9145366B2/en active Active
- 2012-06-05 KR KR1020197007630A patent/KR102059366B1/ko active Active
- 2012-06-05 SI SI201231114T patent/SI3000808T1/en unknown
- 2012-06-05 CN CN201610967348.7A patent/CN106518759B/zh active Active
- 2012-06-05 WO PCT/US2012/040833 patent/WO2012170377A1/en not_active Ceased
- 2012-06-05 PT PT192144053T patent/PT3683209T/pt unknown
- 2012-06-05 DK DK12796374.2T patent/DK2718265T3/en active
- 2012-06-05 RU RU2013158640/04A patent/RU2602083C2/ru active
- 2012-06-05 PL PL19214405T patent/PL3683209T3/pl unknown
-
2013
- 2013-12-03 IL IL229775A patent/IL229775A/en active IP Right Grant
-
2015
- 2015-08-24 US US14/833,222 patent/US9776969B2/en active Active
-
2016
- 2016-01-14 CY CY20161100037T patent/CY1117177T1/el unknown
- 2016-01-15 SM SM201600013T patent/SMT201600013B/it unknown
-
2017
- 2017-04-12 AU AU2017202414A patent/AU2017202414B2/en active Active
- 2017-08-31 US US15/692,255 patent/US10246416B2/en active Active
- 2017-11-13 HR HRP20171740TT patent/HRP20171740T1/hr unknown
- 2017-11-15 CY CY20171101202T patent/CY1119605T1/el unknown
-
2018
- 2018-02-08 JP JP2018020595A patent/JP6510094B2/ja active Active
- 2018-10-15 AU AU2018250355A patent/AU2018250355B2/en active Active
-
2019
- 2019-03-13 US US16/352,705 patent/US10738010B2/en active Active
- 2019-04-03 JP JP2019070979A patent/JP6816195B2/ja active Active
-
2020
- 2020-02-03 CY CY20201100087T patent/CY1122639T1/el unknown
- 2020-02-06 HR HRP20200197TT patent/HRP20200197T1/hr unknown
- 2020-07-06 US US16/921,273 patent/US11267785B2/en active Active
- 2020-07-07 AU AU2020204528A patent/AU2020204528B2/en active Active
- 2020-12-23 JP JP2020213442A patent/JP7039682B2/ja active Active
-
2021
- 2021-12-08 CY CY20211101079T patent/CY1124874T1/el unknown
-
2022
- 2022-01-31 US US17/589,118 patent/US20230002323A1/en active Pending
- 2022-03-09 JP JP2022035813A patent/JP7284309B2/ja active Active
-
2023
- 2023-05-18 JP JP2023081959A patent/JP7685552B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1117177T1 (el) | Διεργασια για την παρασκευη [(3-υδροξυπυριδινο-2-καρβονυλ)αμινο]αλκανοϊκων οξεων, εστερων και αμιδιων | |
| CY1123208T1 (el) | Κυκλικα παραγωγα εστερων βορονικου οξεος, μεθοδος για την παρασκευη και θεραπευτικες χρησεις αυτων | |
| CY1121695T1 (el) | Ενωσεις και συνθεσεις ως αναστολεις κινασης c-kit | |
| CY1122983T1 (el) | Νεες ενωσεις | |
| EA201170872A1 (ru) | Ингибиторы протеинкиназы | |
| CY1120029T1 (el) | Παραγωγα 6-(5-υδροξυ-1η-πυραζολ-1-υλ) νικοτιναμιδιου και χρηση τους ως αναστολεις phd | |
| UA110983C2 (uk) | Похідна 1,2,3,4-тетрагідрохіноліну, придатна для лікування діабету | |
| MX2018001491A (es) | Metodos para la preparacion de acidos biliares y derivados de los mismos. | |
| CY1119056T1 (el) | Παραγωγα 2',4',-διφθορο-2'-μεθυλ υποκατεστημενου νουκλεοσιδιου ως αναστολεις αντιγραφης hcv rna | |
| EA201790108A1 (ru) | Гетероарильные соединения, пригодные в качестве ингибиторов sumo-активирующего фермента | |
| NZ602266A (en) | Macrocycles as factor xia inhibitors | |
| EA201101497A1 (ru) | Имидазопираны для применения в качестве ингибиторов киназ | |
| NZ603478A (en) | 2 -aminopyridine derivatives useful as inhibitors of atr kinase | |
| EA201270800A1 (ru) | С-28 амиды модифицированных производных с-3 бетулиновой кислоты в качестве ингибиторов созревания вич | |
| MX2012008221A (es) | Inhibidores de virus flaviviridae. | |
| MX378717B (es) | Acidos carboxilicos heterociclicos como activadores de guanilato ciclasa soluble. | |
| CY1113494T1 (el) | 8-ΕΤΕΡΟΑΡΥΛΟ-3-ΑΛΚΥΛΟ-1,3-ΔΙΥΔΡΟ-ΙΜΙΔΑΖΟ[4,5-c]ΚΙΝΟΛΙΝ-2-ΟΝΕΣ ΩΣ ΑΝΑΣΤΟΛΕΙΣ ΚΙΝΑΣΩΝ ΡΙ-3 | |
| MX2012008211A (es) | Inhibidores de virus flaviviridae. | |
| MX2012000959A (es) | Inhibidores de los virus flaviviridae. | |
| CY1116989T1 (el) | C-28 αμινες c-3 τροποποιημενων παραγωγων βετουλινικου οξεος ως αναστολεις hiv ωριμανσης | |
| EA201001769A1 (ru) | Производные хинолинов и хиноксалинов в качестве ингибиторов протеинтирозинкиназы | |
| MX2018001145A (es) | Métodos para la preparación de ácidos biliares y derivados de los mismos. | |
| MX2016009759A (es) | Inhibidores de neprilisina. | |
| EA201270816A1 (ru) | Производные бензамида и их применение в качестве ингибиторов hsp90 | |
| MA32588B1 (fr) | Derives azotes de la pancratistatine |